Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J, Amini B, Day SF, Jackson TL, Thomas PS, Willis BJ, Throckmorton WR, Daw NC, Bevers TB, Strong LC. Bojadzieva J, et al. Among authors: jackson tl. Fam Cancer. 2018 Apr;17(2):287-294. doi: 10.1007/s10689-017-0034-6. Fam Cancer. 2018. PMID: 28988289
Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.
Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R. Wheler JJ, et al. Among authors: jackson tl. Cancer Chemother Pharmacol. 2014 Mar;73(3):495-501. doi: 10.1007/s00280-014-2384-1. Epub 2014 Jan 17. Cancer Chemother Pharmacol. 2014. PMID: 24435060 Free PMC article. Clinical Trial.
Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.
García-Layana A, Chi GC, Kodjikian L, Parravano M, Chow D, Jackson TL, Danzig C, Paris LP, Mirt M, Henry-Szatkowski M, Lewis HB, Gentile B. García-Layana A, et al. Among authors: jackson tl. Ophthalmic Res. 2025;68(1):13-22. doi: 10.1159/000541349. Epub 2024 Nov 21. Ophthalmic Res. 2025. PMID: 39571557 Free article.
Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T.
Eleftheriadou A, Riley D, Zhao SS, Austin P, Hernández G, Lip GYH, Jackson TL, Wilding JPH, Alam U. Eleftheriadou A, et al. Among authors: jackson tl. Diabetologia. 2025 Jan;68(1):249-250. doi: 10.1007/s00125-024-06314-1. Epub 2024 Nov 7. Diabetologia. 2025. PMID: 39505765 No abstract available.
300 results